文献速递乳腺癌

NSABP B-47:HER2阴性高危乳腺癌辅助化疗联合曲妥珠单抗的III期随机试验

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2.
PubMed 文献 · J Clin Oncol · 2019-12-10

NSABP B-47旨在评估在HER2阴性(IHC 1+或2+且FISH阴性)高危原发性浸润性乳腺癌患者中,辅助化疗联合曲妥珠单抗是否改善无浸润性疾病生存(IDFS)。共3270例女性随机接受化疗联合或不联合1年曲妥珠单抗。中位随访46个月,联合曲妥珠单抗未改善IDFS、无远处复发间期或总生存,且未增加意外毒性。

要点

  • 在HER2阴性(IHC 1+或2+且FISH阴性)高危乳腺癌中,辅助化疗联合曲妥珠单抗未改善IDFS。
  • 曲妥珠单抗对无远处复发间期和总生存均无获益。
  • 亚组分析(HER2 IHC表达水平、淋巴结状态、激素受体状态)未见获益差异。

核心结论

  • 在非HER2过表达的浸润性乳腺癌女性中,辅助化疗联合曲妥珠单抗未改善无浸润性疾病生存、无远处复发间期或总生存。
  • 曲妥珠单抗对无IHC 3+或FISH比值扩增的乳腺癌患者无获益。

研究设计与样本

  • III期随机对照试验(NSABP B-47/NRG Oncology),共纳入3270例高危原发性浸润性乳腺癌女性。
  • 随机分配至辅助化疗联合或不联合1年曲妥珠单抗。
  • 入组标准包括IHC评分1+或2+且FISH比值<2.0,或未进行FISH时HER2基因拷贝数<4.0。
  • 化疗方案为多西他赛联合环磷酰胺,或阿霉素联合环磷酰胺后序贯每周紫杉醇12周。

主要发现

  • 按HER2 IHC表达水平、淋巴结受累或激素受体状态分层,结果均无差异。
  • 联合曲妥珠单抗未出现意外毒性。

临床怎么用

  • 对于HER2阴性(IHC 1+或2+且FISH阴性)的高危浸润性乳腺癌患者,不应在辅助化疗基础上常规添加曲妥珠单抗。
  • 曲妥珠单抗仅推荐用于HER2阳性(IHC 3+或FISH扩增)乳腺癌。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Adjuvant trastuzumab reduces invasive breast cancer (IBC) recurrence and risk for death in patients with HER2-amplified or overexpressing IBC. A subset of patients in the landmark trastuzumab adjuvant trials who originally tested HER2-positive but were HER2-negative by central HER2 testing appeared to possibly benefit from trastuzumab. The objective for the NSABP B-47 trial was to determine whether the addition of trastuzumab to adjuvant chemotherapy (CRx) would improve invasive disease-free survival (IDFS) in patients with HER2-negative breast cancer. PATIENTS AND METHODS: A total of 3,270 women with high-risk primary IBC were randomly assigned to CRx with or without 1 year of trastuzumab. Eligibility criteria included immunohistochemistry (IHC) score 1+ or 2+ with fluorescence in situ hybridization ratio (FISH) < 2.0 or, if ratio was not performed, HER2 gene copy number < 4.0. CRx was either docetaxel plus cyclophosphamide or doxorubicin and cyclophosphamide followed by weekly paclitaxel for 12 weeks. RESULTS: At a median follow-up of 46 months, the addition of trastuzumab to CRx did not improve IDFS (5-year IDFS: 89.8% with CRx plus trastuzumab [CRxT] v 89.2% with CRx alone; hazard ratio [HR], 0.98; 95% CI, 0.76 to 1.25; P = .85). These findings did not differ by level of HER2 IHC expression, lymph node involvement, or hormone-receptor status. For distant recurrence-free interval, 5-year estimates were 92.7% with CRxT compared with 93.6% for CRx alone (HR, 1.10; 95% CI, 0.81 to 1.50; P = .55) and for overall survival (OS) were 94.8% with CRxT and 96.3% in CRx alone (HR, 1.33; 95% CI, 0.90 to 1.95; P = .15). There were no unexpected toxicities from the addition of trastuzumab to CRx. CONCLUSION: The addition of trastuzumab to CRx did not improve IDFS, distant recurrence-free interval, or OS in women with non-HER2-overexpressing IBC. Trastuzumab does not benefit women without IHC 3+ or FISH ratio-amplified breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fehrenbacher L, Cecchini RS, Geyer CE, et al. NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2. J Clin Oncol. 2019. PMID: 31821109. doi:10.1200/JCO.19.01455

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。